Puma Biotechnology Inc

$PBYI
Biotechnology: Pharmaceutical Preparations
Health Care

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

IPO Year:

Exchange: NASDAQ

Website: pumabiotechnology.com

Peers

$ONCY

Recent Analyst Ratings for Puma Biotechnology Inc

DatePrice TargetRatingAnalyst
9/28/2021$11.00Neutral → Buy
Citigroup
9/28/2021Neutral → Buy
Citigroup
8/6/2021$13.00 → $6.00Sector Perform
RBC Capital
8/6/2021$9.00 → $8.00Sell
Goldman Sachs
See more ratings

Puma Biotechnology Inc Press Releases

Fastest customizable press release news feed in the world

See more
  • Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that clinical data on neratinib will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025. The AACR Annual Meeting will be held at the McCormick Place in Chicago, Illinois, from April 25–30, 2025. The title of the poster that will be presented is now available on the AACR Annual Meeting website at https://www.abstractsonline.com/pp8/#!/20273/presentation/10447. The full poster will be available on the Puma website concurrent with the live presentation. Poster Session: First-in-Human Phase I Clinical Trials 1 Abstract CT071: Title: Phase I trial of trastuzumab deruxtecan in co

    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on March 4, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of an inducement restricted stock unit award covering 3,500 shares of Puma common stock to one new non-executive employee. The award was granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit award vests over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award's vesting commencement date, March 1, 2025, a

    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:00 p.m. ET on Tuesday, March 11, at Barclays 27th Annual Global Healthcare Conference. The conference will be held at the Loews Miami Beach. A live webcast of the presentation will be available on the Puma Biotechnology website at https://www.pumabiotechnology.com. The presentation will be archived on the website and available for replay for 30 days. About Puma Biotechnology Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovat

    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2024. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2024 compared to the fourth quarter and full year 2023. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net for the fourth quarter of 2024 was $54.4 million, compared to $53.2 million in the fourth quarter of 2023. Product revenue, net for the full year 2024 was $195.2 million, compared to $203.1 million in 2023. Based on accounting principles generally accepted in the United Stat

    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Puma Biotechnology to Present at TD Cowen's 45th Annual Health Care Conference

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 11:10 a.m. ET on Wednesday, March 5, at the TD Cowen 45th Annual Health Care Conference. The conference will be held March 3–5, 2025 at the Boston Marriott Copley Place in Boston. A live webcast of the presentation will be available on the Puma Biotechnology website at https://www.pumabiotechnology.com. The presentation will be archived on the website and available for replay for 30 days. About Puma Biotechnology Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the deve

    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, February 27, 2025, following the release of its fourth quarter and full year 2024 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available approx

    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on February 4, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 7,250 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award's vesting commencement date, February 1

    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on January 2, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 24,375 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award's vesting commencement date, January 1,

    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Puma Biotechnology's NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Cervical Cancer were updated to include an addition involving neratinib (NERLYNX®). The updated NCCN Practice Guidelines for Cervical Cancer include neratinib monotherapy for use as second-line or subsequent therapy for recurrent or metastatic disease as an option for patients with HER2-mutated tumors with a designation of Category 2A. The NCCN Guidelines Category of Preference is designated as "useful in certain circumstances" as a treatment option for patients with HER2-mutated tumors. This

    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on December 2, 2024, the Compensation Committee of Puma's Board of Directors approved the grant of an inducement restricted stock unit award covering 7,500 shares of Puma common stock to one new non-executive employee. The award was granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit award vests over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award's vesting commencement date, December 1,

    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

Puma Biotechnology Inc Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

Puma Biotechnology Inc Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

Puma Biotechnology Inc SEC Filings

See more

Puma Biotechnology Inc Leadership Updates

Live Leadership Updates

See more
  • Puma Biotechnology to Join Russell 3000 Index

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, is set to join the broad-market Russell 3000® Index at the conclusion of Russell Investments' annual reconstitution of its comprehensive set of U.S. and global equity indexes on June 28 and effective after U.S. markets open on July 1, according to a preliminary list of additions posted on May 24. "We are very pleased to be included in the widely referenced Russell Indexes," said Alan H. Auerbach, Chief Executive Officer and President of Puma Biotechnology. "We believe that inclusion in the Russell 3000 will benefit our stockholders by increasing liquidity and providing exposure to a broader base of institutional investor

    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Summit Therapeutics Appoints Experienced Clinical Leader Dr. Alessandra Cesano to its Board of Directors

    Menlo Park, California, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Dr. Alessandra Cesano, MD, PhD, has been appointed to its Board of Directors, effective immediately. "Dr. Cesano compliments our Board of Directors with her decades of extensive experience in the global clinical development of oncology drugs," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "As we intend to expand our pipeline product portfolio into oncology, we are excited to add the wisdom and expertise that Alessandra can bring to our impressive leadership team. Her experience in developing both large and

    $EPIX
    $PBYI
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Toragen, Inc. Announces the Appointment of Board of Directors and Senior Staff

    Toragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus ("HPV") Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus ("HPV"), announced today the appointment of Mr. Paul Engler, of Amarillo, Texas, to the Board of Directors of the Company. Additionally, Toragen announced the appointment of Cheryl Collett as CFO, effective June 20, 2022, and Dr. Richard Lumpkin as Director, Research & Development, effective July 1, 2022. Mr. Engler is the founder of Cactus Feeders. In 1960, he started the first cattle-feeding oper

    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • ONK Therapeutics Appoints Hugh O’Dowd as Independent Chairman

    GALWAY, Ireland & SAN DIEGO--(BUSINESS WIRE)--ONK Therapeutics Ltd, an innovative natural killer (NK) cell therapy company, today announced that it has appointed Hugh O’Dowd as Director and independent Non-executive Chairman of its Board of Directors. US-based Mr. O’Dowd brings significant experience and a background in the life sciences industry to the ONK Therapeutics’ Board in particular building organizations and commercialization of oncology therapeutics. His experience and strategic insights will be invaluable to ONK as it executes on its growth ambitions, progressing its novel, off-the-shelf, dual-targeted, natural killer (NK) cell therapy platform towards human clinical tri

    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

Puma Biotechnology Inc Financials

Live finance-specific insights

See more
  • Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2024. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2024 compared to the fourth quarter and full year 2023. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net for the fourth quarter of 2024 was $54.4 million, compared to $53.2 million in the fourth quarter of 2023. Product revenue, net for the full year 2024 was $195.2 million, compared to $203.1 million in 2023. Based on accounting principles generally accepted in the United Stat

    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, February 27, 2025, following the release of its fourth quarter and full year 2024 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available approx

    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Puma Biotechnology Reports Third Quarter 2024 Financial Results

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2024. Unless otherwise stated, all comparisons are for the third quarter of 2024 compared to the third quarter of 2023. Product revenue, net consists entirely of sales revenue from NERLYNX®, Puma's first commercial product. Product revenue, net in the third quarter of 2024 was $56.1 million, compared to $51.6 million in the third quarter of 2023. Product revenue, net in the first nine months of 2024 was $140.8 million, compared to $149.9 million in the first nine months of 2023. Based on accounting principles generally accepted in the United States (GA

    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, November 7, 2024, following the release of its third quarter 2024 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available shortly after complet

    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Puma Biotechnology Reports Second Quarter Financial Results

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2024. Unless otherwise stated, all comparisons are for the second quarter 2024 compared to the second quarter 2023. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net in the second quarter of 2024 was $44.4 million, compared to product revenue, net of $51.6 million in the second quarter of 2023. Product revenue, net in the first six months of 2024 was $84.6 million, compared to $98.3 million in the first six months of 2023. Based on accounting principles generally accepted in th

    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 1, 2024, following the release of its second quarter 2024 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available approximately one hou

    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Puma Biotechnology Reports First Quarter Financial Results

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2024. Unless otherwise stated, all comparisons are for the first quarter 2024 compared to the first quarter 2023. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net in the first quarter of 2024 was $40.3 million, compared to product revenue, net of $46.8 million in the first quarter of 2023. Based on accounting principles generally accepted in the United States (GAAP), Puma reported a net loss of $4.8 million, or $0.10 per basic and diluted share, for the first quarter of 2024,

    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 2, 2024, following the release of its first quarter 2024 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available approximately one hour af

    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2023. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2023 compared to the fourth quarter and full year 2022. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net for the fourth quarter of 2023 was $53.2 million, compared to $53.7 million in the fourth quarter of 2022. Product revenue, net for the full year 2023 was $203.1 million, compared to $200.0 million in 2022. Based on accounting principles generally accepted in the United Stat

    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results

    Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, February 29, 2024, following the release of its fourth quarter and full year 2023 financial results. The call may be accessed by dialing (877) 709-8150 (domestic) or (201) 689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available appr

    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

Puma Biotechnology Inc Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more